Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received…

Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more

Estimated

~$10 – $8,750

Olema Pharmaceuticals, Inc.NCT07085767

Phase 2

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that h…

Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more

Estimated

~$10 – $7,500

Nancy Lin, MDNCT06176261

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used f…

HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more

Estimated

~$10 – $750

Mayo ClinicNCT06388122

Phase 2

Impact of Neoadjuvant Endocrine Therapy on Surgical Outcomes in Patients With Stage 2 to 3 Invasive Lobular Carcinoma: A Prospective Study

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (…

Breast CancerHER2-negative Breast CancerHER2 Negative Breast Carcinoma+2 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07483307

Phase 1

A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer

The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.

Metastatic Breast CancerStage IV Breast CancerBreast Cancer+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06678269

ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)

Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical tr…

HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more

Estimated

~$10 – $675

University of California, San FranciscoNCT06774027

Phase 1

SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic…

Pancreatic Adenocarcinoma MetastaticBRCA1 MutationBRCA2 Mutation+17 more

Estimated

~$10 – $8,750

General Oncology, Inc.